Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

Non-alcoholic fatty liver disease (NAFLD) has become an epidemic, much like other non-
communicable diseases (NCDs), such as cancer, obesity, diabetes, and cardiovascular …

Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common liver
disease globally and is currently estimated to affect 38% of the global population. Only a …

Non-alcoholic fatty liver disease (NAFLD) is not only a consequence of insulin resistance,
but it is also an important cause of insulin resistance and major non-communicable diseases …

Nonalcoholic fatty liver disease (NAFLD) has reached epidemic proportions worldwide.
NAFLD and type 2 diabetes mellitus (T2DM) are known to frequently coexist and act …

Background Studies have reported a significant association between non-alcoholic fatty liver
disease (NAFLD) and increased incidence of cardiovascular disease (CVD). However, the …

Background & Aims The prevalence of non-alcoholic fatty liver disease (NAFLD) is
increasing. We aimed to estimate the pooled global NAFLD incidence. Methods We …

Non-alcoholic fatty liver disease (NAFLD) is a public health problem worldwide. This
narrative Review provides an overview of the current literature to support the notion that …

Background The prevalence of non‐alcoholic fatty liver disease (NAFLD) is increasing in
parallel with obesity and type 2 diabetes. Aim To review the global epidemiology of NAFLD …

To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for
treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we …